If cut down to the bone, our lives are all about finding the best way forward. Now, when you work with such a progressive template, you kind of give yourself a generous chance to learn and grow significantly over time, and that in turn, can produce some interesting by-products. These by-products can also come in various different iterations, except picking from what we have seen so far, we are still yet to see anything as interesting as technology. You see, even before it became the ultimate centerpiece of our lives, technology boasted a clear tendency of breaking the mould. By doing so, it would put us in a position where we had a chance to achieve anything we desired. While this dynamic was always evident on the holistic scale, it eventually made its way in and around the granular areas, including the medical sector. Technology’s foray into healthcare materialized amid a lot of doubt, and rightfully so. After all, how can we just tinker with something so sensitive? Well, all those doubts will soon see the door, as the medical landscape kickstarted a journey away from its obsolete methods. This ushered us into a whole new era, but looking at a recent funding, we can safely say there is still a lot more left in store.
IntelyCare, a Massachusetts-based company, has successfully secured over $115 in Series C financing. Led by global investment firm and asset manager, Janus Henderson, the round saw further participation coming from the likes of Longitude Capital, Leeds Illuminate, Endeavour Vision, Revelation Partners, and Kaiser Permanente Ventures. IntelyCare is known for using data science to deal with staffing shortages and all the factors behind it. In a more actionable sense, the company achieves its goal by giving nurses greater control over their work schedule and remuneration. On the other hand, it also ensures that the medical institution is flexible in terms of the approach towards professionals, and therefore has a healthy work environment. According to certain reports, IntelyCare will use the cash injection to expand across more markets. The company is currently operating in 28 states, but if everything goes well, it should be active in 36 states by the end of 2022.
“In 2016 we began working on a platform to disrupt an industry that was slow to innovate. We knew that a technology solution could change lives for both sides of the market and we’re seeing that vision come to fruition as we now have over 30,000 nursing professionals working with IntelyCare at over 1,600 facilities across the country,” said David Coppins, IntelyCare’s CEO and co-founder. “We’ll use this investment to continue redefining the future of work for our nation’s nurses.”
As IntelyCare also incentivizes nurses through benefits like education, healthcare, and retirement, a chunk of the new funds is expected to go towards increasing those opportunities.
